Liquidia Corporation Common Stock vs Navitas Semiconductor Corporation Common Stock — how do they compare? Liquidia Corporation Common Stock trades at $33.69 (market cap $3.04B), while Navitas Semiconductor Corporation Common Stock trades at $9.02 (market cap $2.45B). The key difference: Liquidia Corporation Common Stock is the larger of the two by market cap, and Navitas Semiconductor Corporation Common Stock is more actively traded (21,189,620 versus 21,111,778). Which is the better fit depends on your goals — on Pluang, investors hold Liquidia Corporation Common Stock for 0 Days and Navitas Semiconductor Corporation Common Stock for 3 Days on average.
| LQDA | NVTS | |
|---|---|---|
Market Cap | $3.04B | $2.45B |
Volume | 21,111,778 | 21,189,620 |
Sector | Health | Technology |
52-Week High | $91.03 | $31.79 |
52-Week Low | $22.02 | $7.14 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $2.94B | $1.90B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Navitas Semiconductor (NVTS) trades at $10.45, up 4.6% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal overall, with moving averages indicating selling pressure, but oscillators suggest some bullish momentum. Fundamentally, the company is in a growth investment phase, reporting negative net income margins and significant cash burn from operations, offset by strong financing inflows. Recent news highlights strategic collaborations with NVIDIA and Microchip for AI data center power solutions and a U.S. Army contract for silicon carbide chip development, positioning NVTS in high-growth power semiconductor markets.
The outlook for NVTS hinges on execution in the AI and defense power semiconductor segments, with a consensus price target of $16.65 implying substantial upside. However, high valuation multiples, persistent losses, and competitive intensity pose significant risks. Investors should weigh the company's promising market positioning against its current lack of profitability and the capital-intensive nature of its expansion.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →Navitas Semiconductor designs and markets gallium nitride and silicon carbide power semiconductors. Its products are used in power conversion and charging for data centers, energy infrastructure, and industrial applications.
Read more on NVTS →